Sandoz acquires Pfizer biosimilar therapy
Holzkirchen, Germany | 15 February 2016

Sandoz has acquired the rights for the development and commercialisation of biosimilar infliximab from Pfizer in the countries that form the European economic area.

Infliximab is a tumour necrosis factor alpha inhibitor that treats autoimmune diseases such as rheumatoid arthritis and psoriasis.

Under the terms of the agreement, Sandoz will complete the clinical study programme and submit the biosimilar to the European Medicines Agency for regulatory approval.

Sandoz acquired the rights to infliximab following Pfizer’s commitments to the European Commission in connection with the acquisition of Hospira to divest the programme.

Richard Francis, global head of Sandoz, said: “Infliximab is one of the most important biologic therapy options for people living with severe autoimmune diseases such as rheumatoid arthritis.”

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization